Dr. Fang served as MicuRx’s Senior Vice President of clinical development since 2017 and Chief Medical Officer from 2020. With over 15 years of experience in antibiotic drug development, he is responsible for the clinical development of MicuRx’s new drugs in the US and global multicenter clinical trials. Dr. Fang was formerly the Chief Medical Officer at Adenium, responsible for clinical development strategy. Prior to Adenium, he served as a director of clinical sciences of Trius, where he was the clinical lead for the development of Sivextro® (tedizolid). He was also an associate director at Cerexa, responsible for early phase clinical studies of ceftaroline. Dr. Fang received his M.D. from the University of California, Los Angeles.